Loading...

Home
ETF
TOVX

TOVX

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

TOVX News

Small-Cap Acquisitions Drive Market Gains

Feb 19 2026Newsfilter

Etsy Sells Depop to eBay for $1.2 Billion

Feb 19 2026Benzinga

Theriva Biologics Receives EMA Support for Phase 3 Trial of VCN-01

Dec 29 2025Benzinga

Theriva Receives EMA Approval for Phase 3 Trial of VCN-01 in Metastatic PDAC

Dec 29 2025Globenewswire

Theriva Receives EMA Approval for Phase 3 Trial of VCN-01 in Metastatic PDAC

Dec 29 2025Newsfilter

Theriva Biologics: Overview of Q3 Earnings

Nov 12 2025Yahoo Finance

Theriva Biologics Addresses Uncommon Market Activity

Oct 24 2025Newsfilter

Stock Market Update: Nasdaq and Dow Futures Rise on Third Day of Shutdown—Focus on Rumble, Rigetti, and Kodiak

Oct 03 2025Benzinga

Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer

May 27 2025Newsfilter

Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

May 14 2025Newsfilter

Theriva Biologics Announces Closing of $7.5 Million Public Offering

May 08 2025Newsfilter

This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

May 08 2025Benzinga

Theriva Biologics announces pricing of $7.5M public offering

May 07 2025SeekingAlpha

Theriva™ Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company's Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Mar 31 2025Newsfilter

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference

Mar 19 2025Newsfilter

Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual

Mar 05 2025Newsfilter